跳至主要内容
临床试验/NCT03456544
NCT03456544Unknown不适用

Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China

Peking University First Hospital1 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2018年10月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
10,000
试验地点
1
主要终点
Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate

研究概览

简要总结

The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Using Vancomycin
  • ≥18 years old

排除标准

  • Medical records were incomplete
  • Had been diagnosed with stage 5 CKD or were regularly receiving dialysis
  • SCr were not being adequately monitored to detect the development of AKI
  • Had undergone nephrectomy

研究组 & 干预措施

VAN-AKI

Patients who had vancomycin associated acute kidney injury.

干预措施: Vancomycin (Drug)

结局指标

主要结局

Vancomycin-associated acute kidney injury(VAN-AKI) occuration rate

时间窗: 1 year

次要结局

  • VAN-AKI detection rate(1 year)
  • TDM detction rate(1 year)
  • 0h Serum creatinine detction rate(1 year)
  • 48h Serum creatinine detction rate(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Cui Yimin

Chief pharmacist

Peking University First Hospital

研究点 (1)

Loading locations...

相似试验